Biomarkers and correlative endpoints for immunotherapy trials.


Journal Article (Review)

Immunotherapies for lung cancer are reaching phase III clinical trial, but the ultimate success likely will depend on developing biomarkers to guide development and choosing patient populations most likely to benefit. Because the immune response to cancer involves multiple cell types and cytokines, some spatially and temporally separated, it is likely that multiple biomarkers will be required to fully characterize efficacy of the vaccine and predict eventual benefit. Peripheral blood markers of response, such as the ELISPOT assay and cytokine flow cytometry analyses of peripheral blood mononuclear cells following immunotherapy, remain the standard approach, but it is increasingly important to obtain tissue to study the immune response at the site of the tumor. Earlier clinical endpoints such as response rate and progression-free survival do not correlate with overall survival demonstrated for some immunotherapies, suggesting the need to develop other intermediary clinical endpoints. Insofar as all these biomarkers and surrogate endpoints are relevant in multiple malignancies, it may be possible to extrapolate findings to immunotherapy of lung cancer.

Full Text

Duke Authors

Cited Authors

  • Morse, MA; Osada, T; Hobeika, A; Patel, S; Lyerly, HK

Published Date

  • 2013

Published In

PubMed ID

  • 23714525

Pubmed Central ID

  • 23714525

Electronic International Standard Serial Number (EISSN)

  • 1548-8756

Digital Object Identifier (DOI)

  • 10.1200/EdBook_AM.2013.33.e287


  • eng

Conference Location

  • United States